Intech Investment Management LLC grew its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 92.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,612 shares of the medical instruments supplier's stock after buying an additional 4,138 shares during the period. Intech Investment Management LLC's holdings in ICU Medical were worth $1,336,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Barclays PLC increased its position in ICU Medical by 15.6% during the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock valued at $10,790,000 after purchasing an additional 8,010 shares during the period. Principal Financial Group Inc. boosted its stake in shares of ICU Medical by 24.6% in the 3rd quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier's stock valued at $23,130,000 after purchasing an additional 25,031 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of ICU Medical by 129.1% during the third quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier's stock worth $2,258,000 after buying an additional 6,981 shares during the period. Jennison Associates LLC bought a new position in ICU Medical during the fourth quarter worth $556,000. Finally, Geode Capital Management LLC lifted its holdings in ICU Medical by 9.6% in the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier's stock valued at $99,687,000 after buying an additional 48,106 shares during the period. 96.10% of the stock is currently owned by institutional investors.
Insider Buying and Selling at ICU Medical
In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,262,119.64. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.70% of the stock is currently owned by company insiders.
ICU Medical Stock Down 0.8 %
Shares of NASDAQ:ICUI traded down $1.17 during trading on Wednesday, reaching $148.71. 250,378 shares of the stock were exchanged, compared to its average volume of 237,514. ICU Medical, Inc. has a 1-year low of $93.36 and a 1-year high of $196.26. The stock has a fifty day moving average of $155.69 and a two-hundred day moving average of $164.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The firm has a market cap of $3.65 billion, a price-to-earnings ratio of -32.54 and a beta of 0.73.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Raymond James set a $97.00 price target on ICU Medical in a report on Wednesday, March 12th. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Tuesday, March 18th. Finally, Jefferies Financial Group raised shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price target for the company in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $168.67.
Check Out Our Latest Stock Report on ICUI
About ICU Medical
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Read More
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
